2021 American Transplant Congress
One-year Outcomes of a Multicenter Trial of Transplantation of Hcv Viremic Kidney Donors into Hcv Uninfected Recipients
*Purpose: As interest in transplantation of Hepatitis C virus (HCV)-viremic kidneys into HCV-uninfected (HCV+ to HCV- KT) recipients increases, understanding clinical outcomes beyond HCV clearance…2021 American Transplant Congress
Exploring the Correlation with Donor Hepatitis C Viral Load and Viral Kinetics in Naïve Kidney Transplantation Recipients
*Purpose: The transplantation of Hepatitis C viremic (HCV) kidneys into uninfected recipients was made possible by effective direct acting anti-viral (DAA) therapy. This study aims…2020 American Transplant Congress
Anticipated Cost Savings of Using Lungs from Hepatitis C-Positive Lung Donors for Hepatitis C-Negative Recipients
*Purpose: We assessed the cost savings generated by additional organ availability due to utilizing lungs from hepatitis-C infected donors for transplantation in comparison to existing…2020 American Transplant Congress
Preemptive Direct Acting Antiviral Therapy as Prophylaxis in Donor HCV-Positive to Recipient HCV-Negative Solid Organ Transplant: a Comprehensive Review
Gastroenterology, Louisiana State University of Health Sciences Shreveport, Shreveport, LA
*Purpose: With the advent of highly effective and safe oral Direct acting Antiviral agents (DAAs), several transplant centers have adopted protocols for using HCV positive…2020 American Transplant Congress
Lowering Meld, Diminishing Length of Stay, and Increasing Liver Transplant Numbers Comes Through the Generosity of Others: Declined HCV-NAT Offers Subsequently Transplanted Have Excellent Outcomes
Transplant Services, Intermountain Healthcare, Murray, UT
*Purpose: There is variability between programs in the acceptance of organ offers. This paper examines offer, acceptance and program performance with HCV NAT positive donor…2020 American Transplant Congress
Financial Analysis of Donor HCV+ Kidney in HCV- Recipients
*Purpose: Use of organs from viremic hepatitis C positive donors (dHCV+) in recipients without HCV has been demonstrated to improve access to kidney transplant (KTx).…2020 American Transplant Congress
A Follow-Up Over Time to the Impact of Reactive Anti-HCV and HCV NAT
LifeShare Transplant Donor Services of Oklahoma, Oklahoma City, OK
*Purpose: A previous review from one U.S. organ procurement organization (OPO) concluded positive HCV test results yielded high rates of authorized/not recovered donors (ANR), low…2020 American Transplant Congress
Hepatitis C Antibody Seroconversion after Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
*Purpose: We aimed to assess factors associated with hepatitis C virus (HCV) seroconversion among HCV seronegative kidney transplant candidates receiving HCV infected donor kidneys.*Methods: This…2020 American Transplant Congress
Racial Differences in Acceptance of Public Health Service (PHS) Increased Risk Kidneys and Hepatitis C (HCV) Nat Positive Kidneys
Tulane University, New Orleans, LA
*Purpose: PHS increased risk kidneys and HCV NAT positive kidneys represent a significant proportion of the donor pool however, acceptance demands explicit patient consent that…2020 American Transplant Congress
Socio-Demographic Disparities in Access to Organs from HCV-Viremic Donors among HCV-Negative Patients
*Purpose: The success of pilot trials of transplanting organs from hepatitis C virus (HCV) viremic donors into HCV-negative recipients (HCV D+/R-) has led to an…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 28
- Next Page »